Vaxart Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
Vaxart, Inc. plans to advance its oral COVID-19 vaccine candidate, VXA-CoV2-1, to Phase 2 testing in Q2 2021. The company reported a cash balance of $126.9 million as of December 31, 2020, reflecting significant capital influx from various funding sources. The fourth-quarter revenue was $356,000, down from $3.9 million in 2019, primarily due to a drop in royalty revenue. The net loss for Q4 2020 was $13.9 million, with R&D expenses increasing to $8.6 million driven by COVID-19 vaccine developments. A strategic conference call is scheduled for March 2, 2021.
- Initiating Phase 2 testing of VXA-CoV2-1 oral COVID-19 vaccine.
- Cash and cash equivalents increased to $126.9 million from $13.5 million in 2019.
- Successful completion of Phase 1 trial with no severe adverse events.
- Strong immune responses demonstrated in Phase 1 trial participants.
- Q4 2020 revenue of $356,000, significantly down from $3.9 million in Q4 2019.
- Net loss increased to $13.9 million in Q4 2020 from $6.4 million in Q4 2019.
- Full year 2020 net loss of $32.2 million compared to $18.6 million in 2019.
- VXA-CoV2-1 oral COVID-19 vaccine candidate targeting both the S and N proteins is planned to advance to Phase 2 testing during Q2 2021
- Cash and cash equivalents of
$126.9 million as of December 31, 2020 - Conference call and webcast focused on our COVID-19 strategy scheduled for Tuesday, March 2, 2021 at 4:30pm ET
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that it plans to initiate the first Phase 2 study of its oral COVID-19 vaccine candidate, VXA-CoV2-1, in 2Q 2021.
Vaxart made this announcement as it provided financial results for the fourth quarter and full year ended December 31, 2020 and provided a corporate update.
“Recently, we have seen the emergence of new SARS-CoV-2 strains, against which some of the leading injectable vaccines offer reduced protection. At the same time, it has become clear that mass vaccinations by needle take a long time, and new strains may emerge faster than many countries’ medical and governmental infrastructure can inject their populations. A better solution is needed given that COVID-19 may be a challenge for years to come,” said Andrei Floroiu, chief executive officer of Vaxart. “As a result of our scientists’ foresight to include both the S and N proteins, VXA-CoV2-1 could be protective against these newly emerging variant strains. We are very excited about the prospect of moving into Phase 2 not only as an oral COVID-19 vaccine candidate, but one with a differentiated mechanism, which could prove to be valuable globally in the fight against coronavirus.”
- VXA-CoV2-1 triggers mucosal immune responses in humans. Mucosal immunity is believed to be the first line of defense against airborne viruses, such as coronavirus and flu, and may also be important in reducing viral shedding and preventing transmission.
- VXA-CoV2-1 targets both the spike protein (S) and nucleoprotein (N). The N protein is more conserved (less prone to mutations) than the S protein, and therefore new viral variants may be less likely to escape protection.
- The N protein is also a good target for T-cell responses. Potent T-cell responses alone may offer multi-variant protection against severe COVID-19 illness.
- Vaxart is also advancing S-only vaccine candidates targeted specifically against variant strains, including one targeting the South African viral strain. These new candidates are expected to generate strong mucosal and serum antibody responses and may be complementary to the potent T-cell inducer VXA-CoV2-1. Vaxart has previously shown that a bivalent oral vaccine using its platform can induce immune responses without interference.
A conference call and webcast focused on our COVID-19 strategy will be held on Tuesday, March 2, 2021 at 4:30pm Eastern Time, Domestic: 877-407-0784, International: 201-689-8560, Conference ID: 13716984, Webcast: http://public.viavid.com/index.php?id=143739.
Recent Business Development Highlights:
Pre-Clinical and Clinical:
- VXA-CoV2-1 Phase 1 trial met its primary and secondary endpoints. The vaccine was generally well-tolerated, with no severe adverse events reported. Results from the trial were presented by Dr. Sean Tucker, Vaxart’s Founder and Chief Scientific Officer, at the New York Academy of Sciences Symposium “The Quest for a COVID-19 Vaccine” in early February 2021. The presentation can be viewed on Vaxart’s corporate website on the Investors page under “Events and Presentations”.
- VXA-CoV2-1 triggered immune responses against SARS-CoV-2 antigens in a majority of subjects, including: CD8+ cytotoxic T-cell response to the S and N proteins (may contribute to long-lasting cross-reactive immunity), activation of B cells that will home to the mucosa, an increase in proinflammatory Th1 cytokines (responsible for creating a productive immune response against viral infection) and IgA responses.
- COVID-19 Hamster Challenge Study data showed that
100% of hamsters receiving two oral doses of Vaxart’s recombinant adenoviral vaccine were protected against systemic weight loss, as well as lung weight gain. Conversely, all unvaccinated animals lost at least8% of their body weight, and all showed evidence of lung disease as measured by relative weight gain in the lungs. Full results from the study will be published when data analysis is complete. - Vaxart’s norovirus vaccine program has been restarted with the addition of a booster dose administered more than 12 months post first vaccination in subjects who participated in the Phase 1b trial. Data are expected to be available in the first half of 2021. Additional studies planned for 2021 include a Phase 1 study in elderly adults age 65+ and a Norovirus Challenge study.
Manufacturing:
- Expanded collaboration with Kindred Biosciences for the manufacturing of VXA-CoV2-1 oral vaccine as well as other vaccine candidates. Under the terms of the expanded agreement, the California plant will be used for scaling the COVID-19 clinical trial material into mid-size bioreactors, and its Kansas plant will be used for manufacturing at a 2000L scale in its single use bioreactors.
- Vaxart entered into an agreement with Attwill Vascular Technologies, LP for processing and lyophilizing certain compounds and further tableting the lyophilized compounds for the Company’s oral COVID-19 vaccine.
Corporate:
- Strengthened the organization, bringing the total number of full-time equivalents to 49 people (including consultants and contractors), by hiring in critical areas, including research, clinical, regulatory, manufacturing, and finance.
Cash Balance:
- Vaxart ended the year with cash and cash equivalents of
$126.9 million compared to$13.5 million as of December 31, 2019. The increase was primarily due to receipts of$97.0 million from the Company’s$100 million at-the-market facility entered into in July 2020,$26.0 million from the exercise of warrants,$9.2 million from the registered direct offering in March 2020, and$4.9 million from the Company’s$250 million at-the-market facility entered into in October 2020 (October 2020 ATM), partially offset by$23.8 million of cash used in operations. - Subsequent to year end, the Company has raised net proceeds of
$65.8 million from the issuance of common stock under the October 2020 ATM.
Financial Results for the Three Months Ended December 31, 2020
- Vaxart reported a net loss of
$13.9 million for the fourth quarter of 2020 compared to$6.4 million for the fourth quarter of 2019. Net loss per share for the fourth quarter of 2020 was$0.13 , unchanged from 2019 due to an increase in the weighted average number of shares outstanding. - Revenue for the fourth quarter was
$356,000 compared to$3.9 million in the fourth quarter of 2019. The decrease was principally due to a reduction in royalty revenue related to Inavir sales in Japan as a result of an abnormally low incidence of seasonal influenza, and a decline in contract revenue from Janssen which was substantially completed by September 30, 2020. - Research and development expenses were
$8.6 million for the fourth quarter of 2020 compared to$3.3 million for the fourth quarter of 2019. The increase was mainly due to manufacturing and clinical trial expenses related to the COVID-19 vaccine candidate. - General and administrative expenses were
$5.1 million for the fourth quarter of 2020 compared to$1.3 million for the fourth quarter of 2019. The increase was mainly due to higher legal and consulting, and an increase in headcount and related costs. - There were no restructuring expenses for the fourth quarter of 2020 compared to
$4.9 million for the fourth quarter of 2019.
Financial Results for the Full Year 2020
- Vaxart reported a net loss of
$32.2 million for full year 2020 compared to$18.6 million for full year 2019. Net loss per share for 2020 was$0.36 , down from$0.86 for 2019 due to the increase in net loss being outweighed by the increase in the weighted average number of shares outstanding during 2020. - Revenue in 2020 was
$4.0 million compared to$9.9 million in 2019. The decrease was principally due to a reduction in royalty revenue related to Inavir sales in Japan due to abnormally low incidences of seasonal influenza in 2020, compared to higher-than-average incidences in 2019. - Research and development expenses were
$19.9 million for 2020 compared to$14.5 million for 2019. The increase was mainly due to higher preclinical, manufacturing and clinical trial expenses related to our COVID-19 vaccine candidate. - General and administrative expenses were
$15.2 million for 2020 compared to$6.2 million for 2019. The increase was mainly due to higher legal and consulting fees and an increase in headcount and related costs. - Restructuring charges for 2019 were
$4.9 million , compared to a net reversal of$849,000 in 2020, principally due to a settlement with Lonza for less than the total amount invoiced. No further restructuring charges or reversals are expected.
About Vaxart
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using tablets that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary tablet vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Its development programs currently include tablet vaccines designed to protect against coronavirus, Norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immuno-oncology indication. Vaxart has filed broad domestic and international patents covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Vaxart’s strategy, prospects, plans and objectives, results from pre-clinical and clinical trials, commercialization agreements and licenses, beliefs and expectations of management are forward-looking statements. These forward-looking statements may be accompanied by such words as “should,” “believe,” “could,” “potential,” “will,” “expected,” “plan” and other words and terms of similar meaning. Examples of such statements include, but are not limited to, statements relating to Vaxart’s ability to develop and commercialize its product candidates and clinical results and trial data (including plans with respect to the COVID-19 vaccine product candidates); expectations relating to Vaxart’s relationship with Emergent BioSolutions Inc., Kindred Biosciences and Attwill Medical Solutions Sterilflow, LP, including their ability to produce cGMP vaccines and the timing thereof; Vaxart’s expectations with respect to the important advantages it believes its oral vaccine platform can offer over injectable alternatives, particularly for coronaviruses such as SARS, MERS and SARS-CoV-2; expectations regarding Vaxart’s ability to develop effective vaccines against new and emerging variant strains; expectations regarding the timing and nature of future developments and announcements, including those related to trials and studies; the potential applicability of results seen in our preclinical studies or trials to those that may be seen in humans or clinical trials; the expected role of mucosal immunity in blocking transmission of COVID-19; and Vaxart’s expectations with respect to the effectiveness of its product candidates, including Vaxart’s potential role in mitigating the impact of COVID-19. Vaxart may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Vaxart makes, including uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical , regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from the clinical studies; decisions by regulatory authorities impacting labeling, manufacturing processes, and safety that could affect the availability or commercial potential of any product candidate, including the possibility that Vaxart’s product candidates may not be approved by the FDA or non-U.S. regulatory authorities; that, even if approved by the FDA or non-U.S. regulatory authorities, Vaxart’s product candidates may not achieve broad market acceptance; that a Vaxart collaborator may not attain development and commercial milestones; that Vaxart or its partners may experience manufacturing issues and delays due to events within, or outside of, Vaxart’s or its partners control, including the recent outbreak of COVID-19; difficulties in production, particularly in scaling up initial production, including difficulties with production costs and yields, quality control, including stability of the product candidate and quality assurance testing, shortages of qualified personnel or key raw materials, and compliance with strictly enforced federal, state, and foreign regulations; that Vaxart may not be able to obtain, maintain and enforce necessary patent and other intellectual property protection; that Vaxart’s capital resources may be inadequate; Vaxart’s ability to resolve pending legal matters; Vaxart’s ability to obtain sufficient capital to fund its operations on terms acceptable to Vaxart, if at all; the impact of government healthcare proposals and policies; competitive factors; and other risks described in the “Risk Factors” sections of Vaxart’s Quarterly and Annual Reports filed with the SEC. Vaxart does not assume any obligation to update any forward-looking statements, except as required by law.
| Contacts | |
| Brant Biehn Vaxart, Inc. 650 550 3500 IR@vaxart.com | David R. Holmes LifeSci Advisors, LLC 646 970 4995 dholmes@lifesciadvisors.com |
Vaxart, Inc.
Condensed Consolidated Balance Sheets
| December 31, 2020 | December 31, 2019 | ||||||||
| (Unaudited) | (1) | ||||||||
| (in thousands) | |||||||||
| Assets | |||||||||
| Cash and cash equivalents | $ | 126,870 | $ | 13,526 | |||||
| Accounts receivable | 334 | 3,619 | |||||||
| Prepaid and other assets | 1,699 | 594 | |||||||
| Property and equipment, net | 1,480 | 210 | |||||||
| Right-of-use assets, net | 6,838 | 1,990 | |||||||
| Intangible assets, net | 15,361 | 17,093 | |||||||
| Total assets | $ | 152,582 | $ | 37,032 | |||||
| Liabilities and stockholders’ equity | |||||||||
| Accounts payable | $ | 2,133 | $ | 852 | |||||
| Accrued and other liabilities | 4,908 | 4,583 | |||||||
| Liability related to sale of future royalties | 14,929 | 16,332 | |||||||
| Operating lease liabilities | 7,208 | 2,313 | |||||||
| Total liabilities | 29,178 | 24,080 | |||||||
| Stockholders’ equity | 123,404 | 12,952 | |||||||
| Total liabilities and stockholders’ equity | $ | 152,582 | $ | 37,032 | |||||
(1) Derived from the audited consolidated financial statements of Vaxart, Inc. for the year ended December 31, 2019, included on the Form 10-K filed with the Securities and Exchange Commission on March 19, 2020.
Vaxart, Inc.
Condensed Consolidated Statements of Operations
| Three Months Ended December 31, | Year Ended December 31, | ||||||||||||||||
| 2020 | 2019 | 2020 | 2019 | ||||||||||||||
| (Unaudited) | (Unaudited) | (Unaudited) | (1) | ||||||||||||||
| (in thousands, except share and per share amounts) | |||||||||||||||||
| Revenue | $ | 356 | $ | 3,916 | $ | 4,046 | $ | 9,862 | |||||||||
| Operating expenses: | |||||||||||||||||
| Research and development | 8,591 | 3,291 | 19,863 | 14,540 | |||||||||||||
| General and administrative | 5,126 | 1,331 | 15,202 | 6,187 | |||||||||||||
| Restructuring and impairment charges and (reversals) | — | 4,920 | (849 | ) | 4,920 | ||||||||||||
| Total operating expenses | 13,717 | 9,542 | 34,216 | 25,647 | |||||||||||||
| Loss from operations | (13,361 | ) | (5,626 | ) | (30,170 | ) | (15,785 | ) | |||||||||
| Other income and expenses, net | (467 | ) | (587 | ) | (1,812 | ) | (2,370 | ) | |||||||||
| Provision for income taxes | (33 | ) | (196 | ) | (238 | ) | (490 | ) | |||||||||
| Net loss | $ | (13,861 | ) | $ | (6,409 | ) | $ | (32,220 | ) | $ | (18,645 | ) | |||||
| Net loss per share, basic and diluted | $ | (0.13 | ) | $ | (0.13 | ) | $ | (0.36 | ) | $ | (0.86 | ) | |||||
| Shares used in computing net loss per share, basic and diluted | 109,663,940 | 47,744,463 | 88,295,762 | 21,569,523 | |||||||||||||
(1) Derived from the audited consolidated financial statements of Vaxart, Inc. for the year ended December 31, 2019, included on the Form 10-K filed with the Securities and Exchange Commission on March 19, 2020.
FAQ
What is Vaxart's plan for its COVID-19 vaccine candidate VXRT?
What were Vaxart's financial results for Q4 2020?
How much cash did Vaxart have at the end of 2020?
When is Vaxart's conference call regarding its COVID-19 strategy?
What were the main drivers behind Vaxart's net loss in 2020?
